
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Morepen Laboratories Expands Its Domestic Portfolio
Details : Ticapen (ticagrelor) mechanism of action involves inhibiting platelet activation and aggregation by reversibly binding to the P2Y12 receptor, to reduce the risk of stroke and heart attack.
Product Name : Ticapen
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 25, 2025
Lead Product(s) : Ticagrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Contact Us!